Zur Rose Group AG provided earnings guidance for the full year 2019. For the year, Zur Rose Group expects revenue including medpex of around CHF 1.6 billion, representing more than 30% growth over last year. In light of the introduction of electronic prescriptions in Germany, management confirms the outlook for 2022. The Zur Rose Group is looking to double the revenue achieved in 2018.